Technical Analysis for SNG - Synairgen Plc

Grade Last Price % Change Price Change
F 5.10 -0.68% -0.04
SNG closed down 0.68 percent on Thursday, March 28, 2024, on 58 percent of normal volume. It ran into resistance at its 50 day moving average.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Gapped Down Weakness 0.00%
20 DMA Resistance Bearish -0.68%
50 DMA Resistance Bearish -0.68%
Gapped Down Weakness -0.68%
Lower Bollinger Band Touch Weakness -0.68%
20 DMA Resistance Bearish -1.45%
50 DMA Resistance Bearish -1.45%
Inside Day Range Contraction -1.45%

   Recent Intraday Alerts

Alert Time
Up 10% about 15 hours ago
Rose Above Previous Day's High about 15 hours ago
Up 5% about 15 hours ago
Up 3% about 15 hours ago
50 DMA Resistance about 15 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Synairgen Plc Description

Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Health Bank Medicine Disease Clinic Diseases Biology Drug Discovery Therapy Respirator Beta Therapies Astrazeneca Respiratory Disease Respiratory Diseases Asthma Chronic Obstructive Pulmonary Disease Fibrosis In Vitro Respiratory Therapy Copd Idiopathic Pulmonary Fibrosis Pulmonology

Is SNG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.5
52 Week Low 4.2
Average Volume 313,128
200-Day Moving Average 6.97
50-Day Moving Average 5.38
20-Day Moving Average 5.30
10-Day Moving Average 5.22
Average True Range 0.90
RSI (14) 45.65
ADX 19.96
+DI 8.39
-DI 8.74
Chandelier Exit (Long, 3 ATRs) 3.89
Chandelier Exit (Short, 3 ATRs) 6.91
Upper Bollinger Bands 5.94
Lower Bollinger Band 4.65
Percent B (%b) 0.34
BandWidth 24.39
MACD Line -0.08
MACD Signal Line -0.05
MACD Histogram -0.0243
Fundamentals Value
Market Cap 10.26 Million
Num Shares 201 Million
EPS -0.05
Price-to-Earnings (P/E) Ratio -101.90
Price-to-Sales 759.00
Price-to-Book 0.69
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.92
Resistance 3 (R3) 6.99 6.44 6.62
Resistance 2 (R2) 6.44 5.98 6.41 6.52
Resistance 1 (R1) 5.77 5.69 6.11 5.70 6.42
Pivot Point 5.23 5.23 5.39 5.19 5.23
Support 1 (S1) 4.55 4.76 4.89 4.49 3.77
Support 2 (S2) 4.01 4.47 3.97 3.67
Support 3 (S3) 3.33 4.01 3.57
Support 4 (S4) 3.27